Ying-Huang Tsai1, Meng-Jer Hsieh2, Chee-Jen Chang3, Yu-Wen Wen3, Han-Chung Hu4, Yen-Nan Chao5, Yhu-Chering Huang6, Cheng-Ta Yang4, Chung-Chi Huang4. 1. Department of Pulmonary and Critical Care Medicine, Chiayi Chang-Gung Memorial Hospital, Chang-Gung Medical Foundation, Puzi City, Taiwan; Department of Respiratory Therapy, Chang-Gung University, Taoyuan City, Taiwan. Electronic address: chestmed@cgmh.org.tw. 2. Department of Pulmonary and Critical Care Medicine, Chiayi Chang-Gung Memorial Hospital, Chang-Gung Medical Foundation, Puzi City, Taiwan; Department of Respiratory Therapy, Chang-Gung University, Taoyuan City, Taiwan. 3. Clinical Informatics and Medical Statistics Research Center, Chang-Gung University, Taoyuan City, Taiwan. 4. Department of Pulmonary and Critical Care Medicine, Linkou Chang-Gung Memorial Hospital, Chang-Gung Medical Foundation, Taoyuan City, Taiwan; Department of Respiratory Therapy, Chang-Gung University, Taoyuan City, Taiwan. 5. Second Division of Centers for Disease Control, the Ministry of Health and Welfare, Taipei City, Taiwan. 6. Department of Pediatrics, Linkou Chang-Gung Memorial Hospital, Chang-Gung Medical Foundation, Taoyuan City, Taiwan.
Abstract
BACKGROUND: Pneumococcal infection is a serious cause of mortality and morbidity in the elderly. A nationwide pneumococcal polysaccharide vaccine (PPV) program for elderly adults aged 75 years and older was conducted in Taiwan in 2008. The efficacy of the PPV in this very elderly population was evaluated. METHODS: The data were analyzed using the Taiwan National Health Insurance Research Database (NHIRD), the cause-of-death registration database and the invasive pneumococcal disease (IPD) notification database of Taiwan's Ministry of Health and Welfare. The efficacy of PPV administration in this very elderly population was evaluated using multivariate logistic regression after propensity score matching (PSM). The rates of IPD, death from IPD, pneumonia hospitalization, death from pneumonia, and all-cause mortality were compared for those who did and did not receive the PPV. RESULTS: Among the 1078,955 eligible people, 318,257 (29.5%) received the PPV, and 760,698 (70.5%) were not vaccinated. Using PSM to adjust for confounding factors, including age, gender, influenza vaccination status, associated chronic diseases and health care utilization, those who received the PPV had significantly lower odds ratios (ORs) for IPD (OR=0.24, 95% CI=0.123-0.461, p<0.001), death from IPD (OR=0.09, 95% CI=0.011-0.704, p<0.022, p<0.001), pneumonia hospitalization (OR=0.40, 95% CI=0.395-0.415, p<0.001), death from pneumonia (OR=0.07, 95% CI=0.059-0.082, p<0.001), and all-cause mortality (OR=0.07, 95% CI=0.069-0.072, p<0.001) compared with those who were not vaccinated. CONCLUSIONS: PPV vaccination in the previous year was associated with a 60% reduction in pneumonia hospitalization, a 76% reduction in IPD, and a greater than 90% reduction in death from pneumonia, IPD and all causes among people over 75 years old in Taiwan. Data from subsequent years in Taiwan and similar populations elsewhere are needed to evaluate the contribution of underlying variations in the mortality rate and the confounding effects of prior disease severity to these findings.
BACKGROUND:Pneumococcal infection is a serious cause of mortality and morbidity in the elderly. A nationwide pneumococcalpolysaccharide vaccine (PPV) program for elderly adults aged 75 years and older was conducted in Taiwan in 2008. The efficacy of the PPV in this very elderly population was evaluated. METHODS: The data were analyzed using the Taiwan National Health Insurance Research Database (NHIRD), the cause-of-death registration database and the invasive pneumococcal disease (IPD) notification database of Taiwan's Ministry of Health and Welfare. The efficacy of PPV administration in this very elderly population was evaluated using multivariate logistic regression after propensity score matching (PSM). The rates of IPD, death from IPD, pneumonia hospitalization, death from pneumonia, and all-cause mortality were compared for those who did and did not receive the PPV. RESULTS: Among the 1078,955 eligible people, 318,257 (29.5%) received the PPV, and 760,698 (70.5%) were not vaccinated. Using PSM to adjust for confounding factors, including age, gender, influenza vaccination status, associated chronic diseases and health care utilization, those who received the PPV had significantly lower odds ratios (ORs) for IPD (OR=0.24, 95% CI=0.123-0.461, p<0.001), death from IPD (OR=0.09, 95% CI=0.011-0.704, p<0.022, p<0.001), pneumonia hospitalization (OR=0.40, 95% CI=0.395-0.415, p<0.001), death from pneumonia (OR=0.07, 95% CI=0.059-0.082, p<0.001), and all-cause mortality (OR=0.07, 95% CI=0.069-0.072, p<0.001) compared with those who were not vaccinated. CONCLUSIONS: PPV vaccination in the previous year was associated with a 60% reduction in pneumonia hospitalization, a 76% reduction in IPD, and a greater than 90% reduction in death from pneumonia, IPD and all causes among people over 75 years old in Taiwan. Data from subsequent years in Taiwan and similar populations elsewhere are needed to evaluate the contribution of underlying variations in the mortality rate and the confounding effects of prior disease severity to these findings.
Authors: Gerhard Falkenhorst; Cornelius Remschmidt; Thomas Harder; Eva Hummers-Pradier; Ole Wichmann; Christian Bogdan Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240
Authors: Myint Tin Tin Htar; Anke L Stuurman; Germano Ferreira; Cristiano Alicino; Kaatje Bollaerts; Chiara Paganino; Ralf René Reinert; Heinz-Josef Schmitt; Cecilia Trucchi; Thomas Vestraeten; Filippo Ansaldi Journal: PLoS One Date: 2017-05-23 Impact factor: 3.240
Authors: Elizabeth T Cafiero-Fonseca; Andrew Stawasz; Sydney T Johnson; Reiko Sato; David E Bloom Journal: PLoS One Date: 2017-10-31 Impact factor: 3.240